ClinicalTrials.gg
Not yet recruitingNCT07711015MFR20MWRUpdated Jul 17, 2026

Myofascial Release and 20-m Speed in Wheelchair Rugby Athletes With Spinal Cord Injury

An interventional study of Myofascial Release in Spinal Cord Injuries (SCI), sponsored by Centro Universitário Augusto Motta. Not yet recruiting at 1 site in Brazil. Open to participants aged 18 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Centro Universitário Augusto Motta · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 18 Years
Sex
All
01

Study summary

This study aims to investigate the effect of myofascial release on sprint performance in wheelchair rugby athletes with spinal cord injury.

Participants will complete a 20-meter sprint test on two different days in a randomized crossover design: one day without myofascial release and one day immediately after the intervention.

The myofascial release will be applied to the upper limb muscles involved in wheelchair propulsion using a handheld device for 90 seconds per muscle group.

Sprint performance will be measured by the time required to complete the 20-meter distance.

The study will compare performance between conditions to determine whether myofascial release improves speed.

02

Conditions studied

  • Spinal Cord Injuries (SCI)

Keywords

  • Rehabilitation
  • Myofascial Release Therapy
  • Para-Athletes
  • Athletic Performance
03

In context

Spinal Cord Injuries

2,025 studies on the registry are indexed under Spinal Cord Injuries; 537 are open to participants now.

This study's planned enrollment of 12 is below the median of 24 across 1,633 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Centro Universitário Augusto Motta is the lead sponsor of 39 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • Aged 18 years or older
  • Cervical spinal cord injury (tetraplegia)
  • Practice of wheelchair rugby for at leastm12 months
  • Participating in team training sessions for at least 3 months prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Musculoskeletal pain
  • Injury that prevents completion of the study protocol.
  • Wounds, pressure ulcers, or skin lesions at the site of myofascial release application
  • Recreational athletes
  • Medical to manual therapy
  • Infection, fever, or acute illness at the time of assessment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Myofascial Release

    Participants will perform a myofascial release session immediately before performing the 20-m wheelchair sprint test.

    Other: Myofascial Release

  • No intervention
    Control

    Participants will perform the 20-m wheelchair sprint test without receiving myofascial release or any other intervention.

Interventions

  • OtherMyofascial Release

    Manual myofascial release will be applied to the upper limb muscles involved in wheelchair propulsion, including the biceps brachii, brachialis, and triceps muscles. The intervention will be performed by a trained physiotherapist using a handheld device, with 90 seconds of application per muscle group. The treatment will be administered immediately prior to the 20-meter wheelchair sprint test

06

What researchers measure

Primary outcomes

  1. Sprint Time (20 meters wheelchair test)

    The 20-m sprint course will be marked on a flat, obstacle-free surface at the same indoor facility where the athletes regularly train, under controlled environmental conditions (wind-free environment and ambient temperature of approximately 26°C). Sprint time (s) will be measured using an electronic timing system consisting of three infrared photocell gates, positioned at the starting line, the 10-m mark, and the finish line. Participants will be instructed to complete the 20-m distance as fast as possible. The test will begin from a stationary position, with the front wheels of the wheelchair positioned immediately behind the starting line. Two trials will be performed, separated by a three-minute passive recovery period. The fastest time recorded across the two trials will be used for statistical analysis.

    Time frame: Immediately after each experimental condition (with and without myofascial release), during the 20-meter sprint test sessions.

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2026, 1 month later.

Of 790 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 1 month is below that.

Counting every sponsor, half of 839 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jul 17, 2026
StartEst.
Aug 17, 2026
Primary completionEst.
Sep 27, 2026
CompletionEst.
Sep 27, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711015
Lead sponsor
Centro Universitário Augusto Motta
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Aug 17, 2026 (estimated)
Primary completion
Sep 27, 2026 (estimated)
Completion
Sep 27, 2026 (estimated)
Last update
Jul 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion